You are here
- Home
- Therapy Areas
Cardiovascular
The following trials provide information to treat various types of cardiovascular diseases, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse A Randomized, Single-Blind, Placebo-Controlled, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics after Multiple Ascending Oral Doses of AZD1656 in subjects with T2DM treated with Metformin
- collapse A Randomized, Single-Blind, Placebo-Controlled, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics after Multiple Ascending Oral Doses of AZD1656 in subjects with T2DM treated with Insulin
- collapse A Randomized, Open, Two-Way Cross-Over, Single-Centre, Phase I Study to Assess the Counter regulatory Response during Hypoglycaemia in Healthy Male Volunteers after a Single Oral Dose of AZD1656 Suspension in Comparison with Insulin Infusion
- collapse A Randomized, Open, Single-Dose, Single-Centre, cross-over, Phase I Study in type 1 diabetes mellitus patients to estimate the extent and rate of absorption of AZD1656 after administration of a tablet formulation in the fasting state and just before food in comparison with an oral suspension of AZD1656
-
expand
An open, single-centre, single group, Phase I study to assess the absorption, distribution, metabolism and excretion (ADME) of AZD1656 after oral administration of 14C-labelled AZD1656 to Type II Diabetes Mellitus patients
- Study Id
- D1020C00008
- Disease
- diabetes mellitus
- Drug Name
- AZD1656
- Study Name
- D1020C00008
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report
-
Dec 10, 2009
- D1020C00008.pdf (490 KB)
- collapse A Randomized, Single-blind, Placebo-Controlled, Multi-centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics after Multiple Ascending Oral Doses of AZD1656 in Japanese T2DM Patients
- collapse A Randomised, Single-Blind, Placebo-Controlled, Single-Centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Ascending Oral Doses of AZD1656 in Japanese Healthy Male Volunteers
- collapse A Randomized, Single-Blind, Placebo-Controlled, Single-Centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics after Multiple Ascending Oral Doses of AZD1656 in T2DM Subjects
- collapse A Randomized, Single-Blind, Placebo-Controlled, Single-Centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Interaction after Single Ascending Oral Doses of AZD1656 in Healthy Male Subjects
- collapse A Randomised, Single-Blind, Placebo-Controlled, Single-Centre Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after high Single Ascending Oral Supratherapeutic Doses of AZD1656 in Male Type 2 Diabetes Mellitus Patients
